Spironolactone Tablet, Film Coated
Product Images NDC 51655-861

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 51655-861). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51655-861-26 (51655 861 26 Rev A 02 23)

Label for spironolactone tablets USP 50 mg, film-coated, supplied in a bottle of 90 tablets. The label includes storage instructions (store at 20°-25°C, protect from light), usage warnings, and repackaging information by Northwind Pharmaceuticals in Indianapolis, IN. The label also features product identifiers such as NDC 51655-861-26 and barcode.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 01)

Chemical structure of spironolactone depicting its steroidal framework with multiple rings, functional groups including a lactone ring, methyl groups, and a thioacetyl substituent.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 02)

A survival probability curve comparing spironolactone (n=822) and placebo (n=841) over 42 months. The x-axis represents time in months, and the y-axis shows probability. The graph includes a log-rank p-value of less than 0.001, indicating statistical significance between the groups.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 03)

A forest plot chart showing hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups in a clinical study comparing spironolactone to placebo. Subgroups include age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot visually compares outcomes favoring spironolactone or placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.